Compare AAON & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAON | ABVX |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | France |
| Employees | N/A | 69 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 11.9B |
| IPO Year | 1995 | N/A |
| Metric | AAON | ABVX |
|---|---|---|
| Price | $103.32 | $126.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $107.75 | ★ $131.31 |
| AVG Volume (30 Days) | 950.3K | ★ 1.7M |
| Earning Date | 05-07-2026 | 03-23-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,442,076,000.00 | N/A |
| Revenue This Year | $21.49 | $52.14 |
| Revenue Next Year | $13.70 | $4,132.27 |
| P/E Ratio | $224.33 | ★ N/A |
| Revenue Growth | ★ 20.11 | N/A |
| 52 Week Low | $62.00 | $65.67 |
| 52 Week High | $150.46 | $148.83 |
| Indicator | AAON | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 50.06 |
| Support Level | $87.14 | $107.67 |
| Resistance Level | $108.50 | $129.73 |
| Average True Range (ATR) | 6.01 | 4.67 |
| MACD | -0.41 | -1.66 |
| Stochastic Oscillator | 11.85 | 1.65 |
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It generates the majority of its revenue from the AAON Oklahoma segment which derives maximum revenue, engineers, manufactures, and sells, semi-custom, and custom HVAC systems, designs and manufactures control solutions, and sells retail parts to customers through retail part stores and online.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.